UroGen Pharma Ltd. (URGN)

UroGen Pharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Net Income	-102.24	-109.78	-110.82	-128.48	-105.15
Depreciation & Amortization	1.71	1.82	1.77	2.04	1.32
Share-Based Compensation	9.34	10.58	23.11	28.03	29.97
Other Operating Activities	14.82	9.83	1.04	-7.47	2.84
Operating Cash Flow	-76.38	-87.56	-84.89	-105.89	-71.02
Capital Expenditures	-0.19	-0.25	-0.75	-1.22	-0.33
Change in Investments	-0.76	1.31	4.82	94.45	-145.1
Other Investing Activities	-	-	-	-	-0.17
Investing Cash Flow	-0.95	1.06	4.07	93.24	-145.59
Share Issuance / Repurchase	116.93	1.51	0.06	16.59	165.33
Debt Issued / Paid	0	95.78	0	0	0
Other Financing Activities	-	-0.16	72.26	-0.07	-0.08
Financing Cash Flow	116.93	97.13	72.32	16.53	165.25
Net Cash Flow	39.6	10.64	-8.5	3.88	-51.36
Free Cash Flow	-76.57	-87.81	-85.64	-107.1	-71.34
Free Cash Flow Margin	-92.57%	-136.45%	-178.27%	-907.71%	-396344.44%
Free Cash Flow Per Share	-2.66	-3.85	-3.83	-4.92	-3.48

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).